Abstract
Background Evidence has suggested the functional role of exosomal miRNAs in cancer diagnosis. This study aimed to determine whether the serum exosomal biomarkers can improve the diagnosis of patients with non-small-cell lung cancer (NSCLC). Materials and Methods The exosomes were extracted from the serum of NSCLC patients (n = 235) and healthy donors (n = 231) using ultracentrifugation and then were evaluated by using transmission electron microscopy, qNano, and western blotting. The serum exosomal miRNA expression was validated using qPCR. Results Exosomal miR-620 was significantly reduced in NSCLC and early-stage NSCLC patients (P < 0.0001) when compared to that of healthy controls, with an area under the curve (AUC) of 0.728 and 0.707, respectively. Exosomal miR-620 expression showed an association with drinking (P=0.008) and distant metastasis (P=0.037). Additionally, the downregulated exosomal miR-620 showed association with chemotherapeutic effect (P=0.044). Conclusion These findings suggest the serum exosomal miR-620 as a promising diagnostic and prognostic noninvasive biomarker in NSCLC patients.
Highlights
80% of patients suffer from non-small-cell lung cancer (NSCLC), which is the most common subtype and a major cause of morbidity and mortality worldwide [1].e 5-year overall survival rate of individuals with local NSCLC was as high as 90%
Serum exosomes isolated from NSCLC patients and healthy donors were characterized by Transmission Electron Microscopy (TEM), qNano, and western blotting analysis
The exosomal miR-620 expression levels were statistically decreased in patients with NSCLC or early NSCLC, possessing relatively high diagnostic efficiency, with an area under the curve (AUC) of 0.728. is indicates that the serum exosomal miR-620 has the potential to act as a biomarker in diagnosing, especially early diagnosis of NSCLC
Summary
80% of patients suffer from non-small-cell lung cancer (NSCLC), which is the most common subtype and a major cause of morbidity and mortality worldwide [1].e 5-year overall survival rate of individuals with local NSCLC (stage 1) was as high as 90%. Evidence has suggested the functional role of exosomal miRNAs in cancer diagnosis. Is study aimed to determine whether the serum exosomal biomarkers can improve the diagnosis of patients with non-small-cell lung cancer (NSCLC). E exosomes were extracted from the serum of NSCLC patients (n 235) and healthy donors (n 231) using ultracentrifugation and were evaluated by using transmission electron microscopy, qNano, and western blotting. E serum exosomal miRNA expression was validated using qPCR. Exosomal miR-620 was significantly reduced in NSCLC and early-stage NSCLC patients (P < 0.0001) when compared to that of healthy controls, with an area under the curve (AUC) of 0.728 and 0.707, respectively. Exosomal miR-620 expression showed an association with drinking (P 0.008) and distant metastasis (P 0.037). Ese findings suggest the serum exosomal miR-620 as a promising diagnostic and prognostic noninvasive biomarker in NSCLC patients Conclusion. ese findings suggest the serum exosomal miR-620 as a promising diagnostic and prognostic noninvasive biomarker in NSCLC patients
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
